Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Jaina Patel was in her early 30s when a bout of bronchitis led to hear losing weight, her job and eventually her sense of ...

Source Reference: Lugogo NL, et al "Characterization of patients with asthma treated with dupilumab in a real-world setting: The RAPID registry" CHEST 2022; DOI: 10.1016/j.chest.2022.08.2185.

Between dupilumab and benralizumab, researchers found a significantly reduced rate of asthma exacerbations in the dupilumab group (1.07 per year vs. 1.47 per year; rate ratio, 0.73; 95% CI, 0.63-0 ...

Moreover, the proportion of patients with dupilumab who experienced 1 or more severe asthma exacerbation compared with placebo was 10% vs 20.8% in spring, 7.3% vs 18.2% in summer, 12.6% vs 22.2% ...

Key takeaways: Asthma exacerbation rates ranged from 0.91 to 1.37 for the placebo group and from 0.32 to 0.58 for the dupilumab group. Exacerbations peaked in winter with placebo and in autumn ...

Dupilumab was shown to consistently reduce the risk of serious asthma exacerbations, improve lung function, and reduce Asthma Control Questionnaire 7 Interviewer-Administered (ACQ-7-IA) score ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Dupilumab, an anti-interleukin-4 receptor alpha monoclonal antibody, met the primary endpoint with a 47.7% lower annualized rate of severe asthma exacerbations and 0.32 L greater absolute change ...

Dupilumab improved nasal polyp outcomes and asthma symptoms more than omalizumab in patients with CRSwNP and asthma, according to the head-to-head EVEREST phase 4 trial.

Review compares patient-important outcomes and assesses evidence among 42 systemic treatments in patients in 93 studies.

Asthma exacerbations and systemic corticosteroid (SCS) prescriptions are significantly reduced in patients who receive dupilumab vs patients who receive omalizumab, benralizumab, or mepolizumab ...